KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares Issued
Ratios

Jazz Pharmaceuticals (JAZZ) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $171.2 million.

  • Jazz Pharmaceuticals' Accumulated Depreciation & Amortization rose 918.22% to $171.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.2 million, marking a year-over-year increase of 918.22%. This contributed to the annual value of $32.8 million for FY2024, which is 789.47% up from last year.
  • According to the latest figures from Q3 2025, Jazz Pharmaceuticals' Accumulated Depreciation & Amortization is $171.2 million, which was up 918.22% from $166.3 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Accumulated Depreciation & Amortization high stood at $171.6 million for Q1 2025, and its period low was $26.7 million during Q4 2021.
  • Over the past 5 years, Jazz Pharmaceuticals' median Accumulated Depreciation & Amortization value was $98.0 million (recorded in 2022), while the average stood at $102.5 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Accumulated Depreciation & Amortization soared by 4278.07% in 2021, and later soared by 33.0% in 2023.
  • Jazz Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $26.7 million in 2021, then grew by 13.48% to $30.3 million in 2022, then rose by 0.33% to $30.4 million in 2023, then rose by 7.89% to $32.8 million in 2024, then skyrocketed by 421.99% to $171.2 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $171.2 million for Q3 2025, versus $166.3 million for Q2 2025 and $171.6 million for Q1 2025.